Novo Nordisk A/S (NYSE:NVO) Rating Lowered to Buy at StockNews.com

Novo Nordisk A/S (NYSE:NVO - Get Free Report) was downgraded by research analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research note issued on Tuesday.

A number of other equities research analysts have also recently weighed in on NVO. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a report on Monday, December 23rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $135.00.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock traded down $4.47 during mid-day trading on Tuesday, hitting $58.41. 25,386,984 shares of the company were exchanged, compared to its average volume of 5,927,298. The company has a market capitalization of $262.13 billion, a PE ratio of 17.76, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. The business has a fifty day moving average of $76.55 and a 200 day moving average of $92.55. Novo Nordisk A/S has a 1-year low of $57.36 and a 1-year high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NVO. Brown Miller Wealth Management LLC grew its position in shares of Novo Nordisk A/S by 38.7% during the 1st quarter. Brown Miller Wealth Management LLC now owns 11,394 shares of the company's stock worth $791,000 after buying an additional 3,178 shares during the period. North Star Investment Management Corp. boosted its stake in Novo Nordisk A/S by 18.2% during the 1st quarter. North Star Investment Management Corp. now owns 20,742 shares of the company's stock worth $1,440,000 after acquiring an additional 3,200 shares during the last quarter. Sound Income Strategies LLC grew its holdings in Novo Nordisk A/S by 69.6% during the first quarter. Sound Income Strategies LLC now owns 914 shares of the company's stock valued at $63,000 after purchasing an additional 375 shares during the period. Dover Advisors LLC bought a new stake in Novo Nordisk A/S in the first quarter valued at approximately $505,000. Finally, Everpar Advisors LLC raised its holdings in Novo Nordisk A/S by 21.5% in the first quarter. Everpar Advisors LLC now owns 4,115 shares of the company's stock worth $286,000 after purchasing an additional 728 shares during the period. Institutional investors own 11.54% of the company's stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.